Exelixis Inc vs Johnson & Johnson
EXEL vs JNJ — side-by-side comparison from reported financials. EXEL leads 6, JNJ leads 3 of 9 comparable metrics.
Exelixis Inc
EXEL · Healthcare
$60.62+2.71%Mixed
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | EXEL | JNJ |
|---|---|---|
| Price | $60.62 | $261.79 |
| Market cap | $15.0B | $631B |
| Revenue (TTM) | $2.44B | $97.9B |
| Revenue growth | +12.9% | +5.6% |
| Net margin | 35.3% | 21.5% |
| Free cash flow | $1.17B | $22.2B |
| Net cash (debt) | — | ($27.8B) |
| 1-year price return | +57.2% | +37.0% |
| P/E | 17.2 | 29.9 |
| P/E vs own history (cheap-side %) | 81% | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | 42% | 26% |
| CV checks passed | 9 of 10 | 10 of 10 |
| Employees | 1,077 | 140,800 |
Full résumé-style profiles: EXEL CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.